Rare diseases are those affecting only a small proportion of the general population. However, it is estimated that there are more than 7,000 rare diseases and, while these may be individually rare, they are collectively common.1,2 In Europe, approximately 1 in 17 people are affected by a rare disease at some point in their life!1,3
In our role as medical communications professionals, we understand that people with rare diseases are often the experts in their own health. When working in rare diseases, we bridge the distance between pharmaceutical and biotech companies and individuals with rare diseases so the rare community is always at the heart of treatment advances.
Due to the limited numbers of, and access to, specialists, individuals are
increasingly becoming experts in their own rare diseases.
People living with rare diseases are often well informed on the latest research, emerging treatment options and prominent unmet needs. As such, patient partnerships are vital to expanding our understanding of rare diseases.
How do we make it matter?
It is a pivotal time for the rare disease community. Many rare diseases are monogenic and therefore offer the possibility of cell- and gene-targeted therapies, a rapidly evolving field with numerous products in development. With this new progress, a significant educational gap is emerging; information on these novel modalities needs to be communicated to healthcare practitioners, patients, and caregivers/care partners.
How do we make it matter?
Many therapies for rare diseases are being developed by companies that may be relatively new to clinical development and marketing, so bridging the gap between scientific research and patient outcomes is essential. To add to the challenge, fast track regulatory approval or orphan designation is common with rare disease products, shortening the clinical trial process and increasing the need for impactful communications.
How do we make it matter?
The nature of rare disease means that clinical trial design can be challenging. Trial populations may be small and heterogeneous, and endpoints unvalidated or unstandardized. To best serve the rare disease community and bring products to market that improve their lives, trials and endpoints need to be meaningful to those living with rare diseases.
How do we make it matter?
References:
For emerging biotechs, a data-centric approach is crucial to successful commercialization.
Read moreThe biotech industry is a highly competitive landscape, with numerous stakeholders vying for attention and resources. As emerging companies gear up to
Read moreA newly published AI roadmap, co-authored by the Healthcare Communications Association (HCA) and Inizio Medical’s...
Read more